SGLT2 inhibitors are well tolerated and associated with a reduction in the risk of kidney disease progression, acute kidney injury, cardiovascular death, or hospitalization for heart failure in patients with or without T2DM, with benefits from all trial populations studied to date considerably outweighing the risk of serious adverse events.29 The gene discussed is SLC5A2; the disease is acute kidney injury.